News

Sartorius, the life science company, impressed investors with robust first-quarter 2025 performance, sending shares notably higher on Wednesday. Revenue increased by 7.7% to €883 million compared to

Gerresheimer reported seemingly contradictory first-quarter 2025 results, with revenue increasing by 11.6% to €520.1 million while simultaneously posting a net loss of €18 million. This apparent

Alnylam Pharmaceuticals has secured a significant victory with the FDA's approval to expand Amvuttra's (vutrisiran) use for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare and

Die Halozyme Therapeutics Aktie verzeichnete am 8. März 2025 einen weiteren Kursanstieg von 1,38 Prozent und notiert aktuell bei 60,98 USD. Der Biotechnologiewert setzt damit seinen positiven Trend

Blueprint Medicines, a biopharmaceutical company headquartered in Cambridge, Massachusetts, recently reported several significant stock transactions by its leadership team. Multiple executives sold

In early March 2025, Merit Medical Systems' leadership team executed significant stock transactions totaling over $7 million. CEO Fred Lampropoulos sold 34,319 shares at prices between $103.75 and

Several high-ranking executives at Penumbra Inc. have recently sold substantial amounts of company stock, with transactions beginning in early March 2025. Board member Arani Bose divested shares

Merit Medical Systems Inc., a medical technology company with a market capitalization of $6.08 billion, has experienced significant stock transactions by its leadership team. The company's chief

Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial